[1]Boon M, Martini C, Dahan A. Recent advances in neuromuscular block during anesthesia. F1000Res. 2018;7:167. Published 2018 Feb 9. 1
[1]Green MS, Venkatesh AG, Venkataramani R. Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution. Case Rep Anesthesiol. 2017; 2017:8197035.
[1]Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010; 27:874–81.
[1]Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010; 111:120–8
[1]Murphy GS, Szokol JW, Franklin M, Marymont JH, Avram MJ, Vender JS. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth Analg. 2004 Jan;98(1):193-200[1]Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol Res. 2000;49(4):455-62. PubMed PMID: 11072806.[1]Sundman E, Witt H, Olsson R, et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000 Apr;92(4):977-84.[1]Eriksson LI. Residual neuromuscular blockade. Incidence and relevance. Anaesthesist. 2000 Apr;49 Suppl 1: S18-9. Review. PubMed PMID: 10840558.[1]Eikermann M, Groeben H, Hüsing J, et al. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology. 2003 Jun;98(6):1333-7.[1]Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology. 1997 Apr;86(4):765-71.
[1]Insinga RP, Joyal C, Goyette A, et al. A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada. BMC Anesthesiol. 2016;16(1):114.
[1]Esteves S, Martins M, Barros F, et al. Incidence of postoperative residual neuromuscular blockade in the postanaesthesia care unit: An observational multicentre study in portugal. Eur J Anaesthesiol 2013, Jan 22
[1]Murphy GS, Brull SJ. Residual neuromuscular block: Lessons unlearned. Part I: Definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg 2010, Jul; 111(1):120-8
[1]Bridion.Ficha técnica. CIMA. AEMPS. Available on: https://cima.aemps.es/cima/dochtml/ft/08466001/FT_08466001.html
[1]Rex C, Bergner UA, Puhringer FK. Sugammadex: a selective relaxant-binding agent providing rapid reversal. Curr Opin Anaesthesiol. 2010; 23:461–5.
[1]Sabo D, Jones RK, Berry J, et al. Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium-induced blockade in patients undergoing abdominal surgery. J Anesthes Clin Res. 2011; 2:140.
[1]Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008; 100:622–30
[1]Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuroniuminduced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010; 110:64–73.
[1]Fortier LP, McKeen D, Turner K, et al. The RECITE study: A canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg 2015,Aug;121(2):366-72.
[1]Batistaki C, Tentes P, Deligiannidi P, et al. Residual neuromuscular blockade in a real-life clinical setting. Correlation with sugammadex or neostigmine administration. Minerva Anestesiol 2015, Sep 22
[1]Ledowski T, O'Dea B, Meyerkort L, et al. Postoperative residual neuromuscular paralysis at an australian tertiary children's hospital. Anesthesiol Res Pract 2015; 2015:410248.
[1]Aytac I, Postaci A, Aytac B, et al. Survey of postoperative residual curarization, acute respiratory events and approach of anesthesiologists. Braz J Anesthesiol 2016;66(1):55-62.
[1]Murphy GS, Szokol JW, Marymont JH, et al. Residual paralysis at the time of tracheal extubation. Anesth Analg 2005, Jun;100 (6):1840-5.
[1]Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006, Feb;102(2):426-9.
[1]Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation:A meta-analysis. Br J Anaesth 2007, Mar;98(3):302-16
[1]Saager L, Maiese EM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J Clin Anesth. 2018 Dec 26; 55:33-41.
[1]Errando CL, Garutti I, Mazzinari G, et al. Residual neuromuscular blockade in the postanesthesia care unit: observational cross-sectional study of a multicenter cohort. Minerva Anestesiol. 2016;82(12):1267-1277.
[1]Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol. 2016 jul;82(7):735-42.
[1]Conjunto mínimo básico de datos de Hospitalización 2015. Available on http://pestadistico.inteligenciadegestion.msssi.es/publicoSNS/comun/DefaultPublico.aspx
[1]Olesnicky BL, Traill C, Marroquin-Harris FB. The effect of routine availability of sugammadex on postoperative respiratory complications: a historical cohort study. Minerva Anestesiol. 2017 Mar;83(3):248 - 254
[1]Bridion. Product Label. Available in: https://ec.europa.eu/health/documents/community-register/2017/20170726138595/anx_138595_es.pdf
[1]Aragón C, Martinez-Ubieto J, Ortega S, et al. Bloqueo muscular residual y sus complicaciones en pacientes revertidos con neostigmina vs. sugammadex. III Congreso Nacional de rehabilitación multimodal. I GERM International Perioperative Medicine Congress. April 2018. Salamanca
[1]BOTPLUS Portalfarma: Colegio Oficial de Farmacéuticos. Available on: https://botplusweb.portalfarma.com/
[1]Boletín Oficial del Estado (BOE) Real Decreto-ley 8/2010. Available on: https://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf
[1]Oblikue eSalud: Información económica del sector sanitario. Available on: http://esalud.oblikue.com/
[1]Berg h, Roed J, Viby-Mogensen J et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997, 41:1095-103
[1]Cappellini I, Ostento D, Loriga B, et al. Comparison of neostigmine vs. sugammadex for recovery of muscle function after neuromuscular block by means of diaphragm ultrasonography in microlaryngeal surgery: A randomised controlled trial. Eur J Anaesthesiol. 2019
[1]Chambers D, Paulden M, Paton F, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess 2010; 14 (39)
[1]Ledowski T, Hillyard S, Kozman A, et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care 2012: 40: 340-3
[1]Fuschs-Buder, Meistelman C, Schreiber JU. Is sugammadex economically viable for routine use. Curr Opin Anaesthesiol 2012; 25(2) 217-20
[1]Mandim BL, Fonseca NM. Economic evaluation of the use of sugammadex in procedures under general anesthesia in Brazil.American Society of Anesthesiologist Annual Meeting 2011: A 121
[1]Paton F, Paulden M, Chambers D. Sugammadex compared with neostigmina/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth 2010; 105: 558-67.
[1]Ozdemir O, Bahar M, Aypar U, et al. Cost-effectiveness analysis comparing Bridion® (Sugammadex) with neostigmine and spontaneous recovery in the reversal of neuromuscular blockade induced by rocuronium/vecuronium. ISPOR 13th European Meeting International Society for Pharmacoeconomics and Outcomes Research Annual European Congress, Nov 6-9-2010 Prague, Czech Republic.Value in Health 2010 Abstract PND22.
[1]Ripoll-Coronado, LI; Análisis de los resultados obtenidos durante la práctica clínica habitual en la reversión del bloqueo neuromuscular superficial con Sugammadex. Valoración de su impacto farmacoeconómico. Thesis, University of Murcia. 2014. Available at: http://hdl.handle.net/10201/40926. Accessed July 30, 2019.
[1]Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, et al. Evidence Anaesthesia Review Group. A systematic review of sugammadex vsneostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015 Dec;70(12):1441-52.[1]Carron M, Zarantonello F, Tellaroli P, et al. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016 Dec; 35:1-12.[1]Hristovska AM, Duch P, Allingstrup M, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017 Aug 14;8:CD012763.